Nuevo Usuario

Recordar Contraseña

Revisiones en Cáncer 00088 / http://dx.doi.org/10.20960/revcancer.00088

Resumen| PDF

Revisión

Estratificación patológica del cáncer de endometrio inicial

Esther Moreno- Moreno, Amanda Rodríguez Villena, Irene Carretero-Barrio, José Palacios, Belén Pérez-Mies

Prepublicado: 2024-11-22

Logo Descargas Número de descargas: 3 Logo Visitas Número de visitas: 12 Citas Citas: 0

Compártelo:

El cáncer de endometrio (CE) es la neoplasia maligna más común del tracto genital femenino y la cuarta más frecuente en mujeres. Tradicionalmente, el CE se ha clasificado en dos tipos: de tipo I, CE de bajo grado (G1-G2), subtipo endometrioide de buen pronóstico, y de tipo II, CE de alto grado (G3), no endometrioides de mal pronóstico. Sin embargo, esta clasificación tradicional no abarca toda la heterogeneidad del CE. En 2013, The Cancer Genomic Atlas (TCGA) describió cuatro subtipos moleculares con diferentes implicaciones pronósticas: CE POLE mutado, CE con inestabilidad de microsatélites, CE copy number low y CE copy-number high. Esta clasificación puede realizarse de forma subrogada en la práctica clínica, lo que mejora la caracterización del CE. La clasificación FIGO de 2023 combina la clasificación molecular subrogada y parámetros histológicos para mejorar la estratificación del riesgo del carcinoma en estadios iniciales y personalizar los tratamientos de manera más efectiva.

Palabras Clave: Carcinoma. Endometrio. Estratificación. Riesgo.

Descargar PDF

Bibliografía
Artículos Relacionados

Ruz-Caracuel I, Ramón-Patino JL, López-Janeiro Á, Yébenes L, Berjón A, Hernández A, et al. Myoinvasive Pattern as a Prognostic Marker in Low-Grade, Early-Stage Endometrioid Endometrial Carcinoma. Cancers (Basel) 2019;11:1845.
DOI: 10.3390/cancers11121845

Organisation Mondiale de la Santé (OMS). Centre International de Recherche sur le Cancer (editors). Female genital tumours. 5th ed. Lyon: International agency for research on cancer; 2020.

Sociedad Española de Oncología Médica (SEOM) El cáncer en cifras [citado el 8 de abril de 2024]. Disponible en: https://www.seom.org/prensa/el-cancer-en-cifras

Amălinei C, Aignătoaei AM, Balan RA, Giuşcă SE, Lozneanu L, Avădănei ER, et al. Clinicopathological significance and prognostic value of myoinvasive patterns in endometrial endometrioid carcinoma. Rom J Morphol Embryol 2018;59:13-22.

Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-7.
DOI: 10.1016/0090-8258(83)90111-7

Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497:67-73.
DOI: 10.1038/nature12113

Gaffney D, Matias-Guiu X, Mutch D, Scambia G, Creutzberg C, Fotopoulou C, et al. 2023 FIGO staging system for endometrial cancer: The evolution of the revolution. Gynecol Oncol 2024;184:245-53.
DOI: 10.1016/j.ygyno.2024.02.002

Organisation Mondiale de la Santé (OMS). Centre International de Recherche sur le Cancer (editors). Female genital tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.

Rosa-Rosa JM, Leskelä S, Cristóbal-Lana E, Santón A, López-García MÁ, Muñoz G, et al. Molecular genetic heterogeneity in undifferentiated endometrial carcinomas. Mod Pathol 2016;29:1390-8.
DOI: 10.1038/modpathol.2016.132

Leskela S, Pérez-Mies B, Rosa-Rosa JM, Cristóbal E, Biscuola M, Palacios-Berraquero ML, et al. Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. Cancers (Basel) 2019;11:964.
DOI: 10.3390/cancers11070964

Brambs CE, Horn L-C, Hiller R, Krücken I, Braun C, Christmann C, et al. Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations. J Cancer Res Clin Oncol 2023;149:15727-36.
DOI: 10.1007/s00432-023-05306-9

Wong RW-C, Talia KL, McCluggage WG. Gastric-type glandular lesions of the female genital tract excluding the cervix: emerging pathological entities. Histopathology 2024;85:20-39.
DOI: 10.1111/his.15174

Berek JS, Matias-Guiu X, Creutzberg C, Fotopoulou C, Gaffney D, Kehoe S, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162:383-94.
DOI: 10.1002/ijgo.14923

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 2015;113:299-310.
DOI: 10.1038/bjc.2015.190

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017;123:802-13.
DOI: 10.1002/cncr.30496

Li JJX, Ip PPC. Endometrial Cancer: An Update on Prognostic Pathologic Features and Clinically Relevant Biomarkers. Surg Pathol Clin 2022;15:277-99.
DOI: 10.1016/j.path.2022.02.006

Casey L, Singh N. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting. Int J Gynecol Pathol 2021;40:5-16.
DOI: 10.1097/PGP.0000000000000710

Vink-Börger E, Den Bakker M, Voorham R, Van Nederveen F, Nagtegaal I. Mismatch repair deficiency: how reliable is the two-antibody approach? A national real-life study. Histopathology 2024;85(4):639-48.
DOI: 10.1111/his.15236

McAlpine J, León-Castillo A, Bosse T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. J Pathol 2018;244:538-49.
DOI: 10.1002/path.5034

Arciuolo D, Travaglino A, Raffone A, Raimondo D, Santoro A, Russo D, et al. TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2022;23:11684.
DOI: 10.3390/ijms231911684

Singh N, Piskorz AM, Bosse T, Jiménez-Linan M, Rous B, Brenton JD, et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. J Pathol 2020;250:336-45.
DOI: 10.1002/path.5375

Kitazono I, Kobayashi Y, Akahane T, Yamaguchi T, Yanazume S, Nohara S, et al. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma. Pathol Res Pract 2022;230:153743.
DOI: 10.1016/j.prp.2021.153743

Huvila J, Orte K, Vainio P, Mettälä T, Joutsiniemi T, Hietanen S. Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier. Hum Pathol 2021;111:98-109.
DOI: 10.1016/j.humpath.2021.02.006

Kasius JC, Pijnenborg JMA, Lindemann K, Forsse D, Van Zwol J, Kristensen GB, et al. Risk Stratification of Endometrial Cancer Patients: FIGO Stage, Biomarkers and Molecular Classification. Cancers (Basel) 2021;13:5848.
DOI: 10.3390/cancers13225848

Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology 2019;75:128-36.
DOI: 10.1111/his.13871

Peters EEM, Nucci MR, Gilks CB, McCluggage WG, Bosse T. Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma. Histopathology 2024.
DOI: 10.1111/his.15272

Santoro A, Angelico G, Travaglino A, Inzani F, Arciuolo D, Valente M, et al. New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines. Cancers (Basel) 2021;13:2623.
DOI: 10.3390/cancers13112623

Cole AJ, Quick CM. Patterns of myoinvasion in endometrial adenocarcinoma: recognition and implications. Adv Anat Pathol 2013;20:141-7.
DOI: 10.1097/PAP.0b013e31828d17cc

Chibbar R, Foerstner S, Suresh J, Chibbar R, Piche A, Kundapur D, et al. Estrogen/Progesterone Receptor Loss, CTNNB1 and KRAS Mutations Are Associated with Local Recurrence or Distant Metastasis in Low-Grade Endometrial Endometrioid Carcinoma. Appl Immunohistochem Mol Morphol 2023;31:181-8.
DOI: 10.1097/PAI.0000000000001102

Travaglino A, Raffone A, Raimondo D, Reppuccia S, Ruggiero A, Arena A, et al. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis. Arch Gynecol Obstet 2022;306:423-31.
DOI: 10.1007/s00404-021-06385-0

De Leo A, De Biase D, Lenzi J, Barbero G, Turchetti D, Grillini M, et al. ARID1A and CTNNB1/β-Catenin Molecular Status Affects the Clinicopathologic Features and Prognosis of Endometrial Carcinoma: Implications for an Improved Surrogate Molecular Classification. Cancers (Basel) 2021;13:950.
DOI: 10.3390/cancers13050950

Köbel M, Tessier-Cloutier B, Leo J, Hoang LN, Gilks CB, Soslow RA, et al. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. Int J Gynecol Pathol 2017;36:555-61.
DOI: 10.1097/PGP.0000000000000369

Post CCB, Stelloo E, Smit VTHBM, Ruano D, Tops CM, Vermij L, et al. Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer. J Natl Cancer Inst 2021;113:1212-20.
DOI: 10.1093/jnci/djab029

Gordhandas S, Kahn RM, Gamble C, Talukdar N, Maddy B, Baltich Nelson B, et al. Clinicopathologic features of endometrial cancer with mismatch repair deficiency. Ecancermedicalscience 2020;14:1061.
DOI: 10.3332/ecancer.2020.1061

Shao Y, Xu R, Shi H, Ye L, Wang H, Lu B. Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment. Virchows Arch 2024.
DOI: 10.1007/s00428-024-03874-w

Buza N. HER2 Testing and Reporting in Endometrial Serous Carcinoma: Practical Recommendations for HER2 Immunohistochemistry and Fluorescent in Situ Hybridization: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol 2021;40:17-23.
DOI: 10.1097/PGP.0000000000000711

Jamieson A, Thompson EF, Huvila J, Gilks CB, McAlpine JN. p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. Int J Gynecol Cancer 2021;31:907-13.
DOI: 10.1136/ijgc-2020-002256

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, et al. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol 2017;24:311-35.
DOI: 10.1097/PAP.0000000000000161

Kondratiev S, Sabo E, Yakirevich E, Lavie O, Resnick MB. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res 2004;10:4450-6.
DOI: 10.1158/1078-0432.CCR-0732-3

Dai Y, Zhao L, Hua D, Cui L, Zhang X, Kang N, et al. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study. Front Immunol 2022;13:1035616.
DOI: 10.3389/fimmu.2022.1035616

Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Mod Pathol 2019;32:396-404.
DOI: 10.1038/s41379-018-0148-x

Jung IK, Kim SS, Suh DS, Kim KH, Lee CH, Yoon MS. Tumor-infiltration of T-lymphocytes is inversely correlated with clinicopathologic factors in endometrial adenocarcinoma. Obstet Gynecol Sci 2014;57:266-73.
DOI: 10.5468/ogs.2014.57.4.266

Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat Commun 2022;13:1373.
DOI: 10.1038/s41467-022-29040-x

Revisión: Plataformas genómicas para decisión terapéutica del carcinoma ductal in situ de mama

Publicado: 2022-07-22 / http://dx.doi.org/

Resumen | PDF

Revisión: Plataformas genómicas y Medicina de Precisión: lecciones aprendidas

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Epidemiología del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF